Clinical Trial Update: Rituximab Combining Bortezomib Versus Rituximab in Management of ITP [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rituximab combined with bortezomib versus rituximab alone for immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Purpura Thrombocytopenic Idiopathic

Drugs mentioned

• Bortezomib (bortezomib)
• Rituximab (rituximab)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic | Phase 3 | Status: UNKNOWN